Trials / Completed
CompletedNCT03695835
A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
A Retrospective and Prospective Study of a New Immunotherapy Regimen (MyVaccx) for Patients With Adenocarcinoma.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (actual)
- Sponsor
- Gary Onik MD · Individual
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunotherapeutic Agents | Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents |
| DEVICE | Ablation | Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents |
Timeline
- Start date
- 2018-04-11
- Primary completion
- 2019-07-08
- Completion
- 2020-06-17
- First posted
- 2018-10-04
- Last updated
- 2020-07-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03695835. Inclusion in this directory is not an endorsement.